• Publications
  • Influence
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
  • Jin Li, S. Qin, Hao Yu
  • Medicine
    Journal of clinical oncology : official journal…
  • 27 September 2016
TLDR
These data show that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy.
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial
TLDR
Among the Chinese patients in this trial, anlotinib appears to lead to prolonged overall survival and progression-free survival, suggesting that anlot inib is well tolerated and is a potential third-line or further therapy for patients with advanced NSCLC.
Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
  • Jin Li, S. Qin, Hao Yu
  • Medicine
    Journal of clinical oncology : official journal…
  • 10 September 2013
TLDR
Apatinib showed improved PFS and OS in heavily pretreated patients with mGC who had experienced treatment failure with two or more chemotherapy regimens, and this trial investigated the safety and efficacy of apatinib, an inhibitor of vascular endothelial growth factor receptor, as a treatment option.
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
TLDR
Anlotinib as a third-line treatment provided significant PFS benefits to patients with RA-NSCLC when compared with the placebo, and the toxicity profiles showed good tolerance.
Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
TLDR
Presence of HTN, proteinuria, or HFS during the first cycle of apatinib treatment was a viable biomarker of antitumor efficacy in metastatic GC patients and showed high calibration and discrimination in predicting overall survival.
A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer
TLDR
This review discusses FRA expression in NSCLC, conjugated FRA agents, monoclonal antibody, and FRA-specific T-cell-based therapeutic strategies aiming to improve the cure rate of F RA-expressingNSCLC.
Cutaneous metastasis from pancreatic cancer: A case report and systematic review of the literature
TLDR
Cutaneous metastasis from pancreatic cancer is a rare finding, often providing the only external indication of an internal malignancy and, therefore, should be considered in the differential diagnosis of skin lesions.
Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer
TLDR
For irinotecan-based regimens in metastatic colorectal cancer, the UGT1A1*28 and UGT2A2*6 locus mutations can be regarded as predictors for irinotspecan-associated severe delayed diarrhea, whereas no association between UGT 1A1 gene polymorphisms and severe neutropenia was observed.
Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis
TLDR
The study showed that GemErlo is associated with reasonable activity in treating patients with locally advanced or metastatic pancreatic cancer, and most of the AEs were tolerable, while some severe AEs needed careful detection.
...
1
2
3
4
5
...